JP2014521070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521070A5 JP2014521070A5 JP2014519031A JP2014519031A JP2014521070A5 JP 2014521070 A5 JP2014521070 A5 JP 2014521070A5 JP 2014519031 A JP2014519031 A JP 2014519031A JP 2014519031 A JP2014519031 A JP 2014519031A JP 2014521070 A5 JP2014521070 A5 JP 2014521070A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- ang2
- plgf concentration
- binding polypeptide
- sorafenib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502686P | 2011-06-29 | 2011-06-29 | |
| US61/502,686 | 2011-06-29 | ||
| PCT/US2012/044673 WO2013003606A1 (en) | 2011-06-29 | 2012-06-28 | Predictive biomarker of survival in the treatment of renal cell carcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014521070A JP2014521070A (ja) | 2014-08-25 |
| JP2014521070A5 true JP2014521070A5 (enExample) | 2015-08-13 |
| JP6069312B2 JP6069312B2 (ja) | 2017-02-01 |
Family
ID=46545468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519031A Active JP6069312B2 (ja) | 2011-06-29 | 2012-06-28 | 腎細胞癌の治療における生存の予測バイオマーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9151761B2 (enExample) |
| EP (1) | EP2726088B1 (enExample) |
| JP (1) | JP6069312B2 (enExample) |
| AU (1) | AU2012275346B2 (enExample) |
| CA (1) | CA2840212A1 (enExample) |
| MX (1) | MX358726B (enExample) |
| WO (1) | WO2013003606A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| SG11201703428SA (en) | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Bispecific antibodies and methods of use in ophthalmology |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| CA2963606A1 (en) * | 2014-11-10 | 2016-05-19 | F.Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| WO2016209972A1 (en) * | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| JP6853789B2 (ja) * | 2015-12-24 | 2021-03-31 | 公益財団法人がん研究会 | マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー |
| CN108496084B (zh) * | 2016-01-25 | 2021-11-05 | 赛诺菲 | 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US5871723A (en) | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
| US6248327B1 (en) | 1998-09-11 | 2001-06-19 | Vanderbilt University | Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| JP5179373B2 (ja) * | 2005-12-15 | 2013-04-10 | アストラゼネカ アクチボラグ | 癌を治療するためのアンジオポエチン−２アンタゴニストとＶＥＧＦ−Ａ、ＫＤＲ、及び／又はＦｌｔ１アンタゴニストの組合せ |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
| KR20120043028A (ko) | 2006-11-10 | 2012-05-03 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 혈관 신생 억제 화합물 |
| WO2008115714A2 (en) * | 2007-03-20 | 2008-09-25 | Apocell, Inc. | Evaluating rtk target drugs |
| JP5699075B2 (ja) * | 2008-05-14 | 2015-04-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ |
-
2012
- 2012-06-28 JP JP2014519031A patent/JP6069312B2/ja active Active
- 2012-06-28 AU AU2012275346A patent/AU2012275346B2/en active Active
- 2012-06-28 MX MX2013015146A patent/MX358726B/es active IP Right Grant
- 2012-06-28 EP EP12737394.2A patent/EP2726088B1/en active Active
- 2012-06-28 US US14/127,157 patent/US9151761B2/en active Active
- 2012-06-28 CA CA2840212A patent/CA2840212A1/en not_active Abandoned
- 2012-06-28 WO PCT/US2012/044673 patent/WO2013003606A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014521070A5 (enExample) | ||
| Goyal et al. | A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma | |
| Chen et al. | Angiopoietin‐like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma | |
| Gavalas et al. | Angiogenesis-related pathways in the pathogenesis of ovarian cancer | |
| Paoluzzi et al. | Response to anti-PD1 therapy with nivolumab in metastatic sarcomas | |
| JP6630397B2 (ja) | アデノウイルスを用いた治療方法 | |
| JP6122776B2 (ja) | 腫瘍細胞由来微小胞 | |
| Kordbacheh et al. | Current and emerging molecular therapies for head and neck squamous cell carcinoma | |
| JP2014521308A5 (enExample) | ||
| PH12019500440A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| EA201000785A1 (ru) | Композиции для доставки в легкие | |
| JP2013501224A5 (enExample) | ||
| JP2015511964A5 (enExample) | ||
| JP2017530372A5 (enExample) | ||
| Liang et al. | Sevoflurane attenuates platelets activation of patients undergoing lung cancer surgery and suppresses platelets-induced invasion of lung cancer cells | |
| Rao et al. | Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer | |
| Yao et al. | Unveiling the role of HGF/c-Met signaling in Non-small cell lung cancer tumor microenvironment | |
| Chen et al. | Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma | |
| EP3216460B1 (en) | Antigen polypeptide for detecting plasma immunological marker-vegfr1 autoantibody and use thereof | |
| Chen et al. | CCL22 and IL-37 inhibit the proliferation and epithelial-mesenchymal transition process of NSCLC A549 cells | |
| Savier et al. | Bi-functional peptides as a new therapeutic tool for hepatocellular carcinoma | |
| Alves et al. | Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective study | |
| Matiash et al. | Functional characteristics and regulated expression of alternatively spliced tissue factor: An update | |
| Daum et al. | Unveiling the immunomodulatory dance: endothelial cells’ function and their role in non-small cell lung cancer | |
| JP2018537519A5 (enExample) |